Results 41 to 50 of about 11,899 (172)

Border Security: The Role of RIPK3 in Epithelium Homeostasis [PDF]

open access: yesFrontiers in Cell and Developmental Biology, 2016
Receptor interacting protein kinase 3 (RIPK3) is a crucial inducer of necroptosis. Its activity is controlled by interaction with other signal adaptors through the "RIP homotypic interaction motif" (RHIM). Recent studies revealed a critical function for RIPK3 in the maintenance of epithelial tissue integrity.
Moriwaki, Kenta   +2 more
openaire   +3 more sources

Roles of RIPK3 in necroptosis, cell signaling, and disease

open access: yesExperimental & Molecular Medicine, 2022
AbstractReceptor-interacting protein kinase-3 (RIPK3, or RIP3) is an essential protein in the “programmed” and “regulated” cell death pathway called necroptosis. Necroptosis is activated by the death receptor ligands and pattern recognition receptors of the innate immune system, and the findings of many reports have suggested that necroptosis is highly
Michael J. Morgan, You-Sun Kim
openaire   +2 more sources

Cytoplasmic MYC is an anti-necroptotic protein

open access: yesMolecular & Cellular Oncology, 2020
Cancer cells are often resistant to necroptosis as well as apotosis, but the underlying mechanisms are not fully understood. We recently revealed an important crosstalk between MYC, a potent oncogene, and receptor-interacting protein kinase 3 (RIPK3), a ...
Eun-Woo Lee   +2 more
doaj   +1 more source

RIPK3 in necroptosis and cancer

open access: yesMolecules and Cells
Receptor-interacting protein kinase-3 is essential for the cell death pathway called necroptosis. Necroptosis is activated by the death receptor ligands and pattern recognition receptors of the innate immune system, leading to significant consequences in inflammation and in diseases, particularly cancer.
Michael J. Morgan, You-Sun Kim
openaire   +2 more sources

RIPK1 and RIPK3 - emerging targets in cancer?

open access: yesMolecular and Cellular Therapies, 2018
RIPK1 and RIPK3 are homologous Ser/Thr kinases, which act in concert within the necrosome complexes to initiate a sub-type of regulated necrosis, termed necroptosis. Necroptosis has gradually emerged as a highly clinically relevant form of necrosis, which can be targeted therapeutically.
Kerem Gurol, Suraj Shah, Alexei Degterev
openaire   +2 more sources

RIPK3 and caspase 8 collaborate to limit herpes simplex encephalitis.

open access: yesPLoS Pathogens, 2022
Invasion of the brain by herpes simplex virus 1 (HSV1) can lead to the development of herpes simplex encephalitis (HSE) that is often associated with significant morbidity and mortality regardless of therapeutic intervention.
Hongyan Guo   +3 more
doaj   +1 more source

RIPK1-RIPK3 mediates myocardial fibrosis in type 2 diabetes mellitus by impairing autophagic flux of cardiac fibroblasts

open access: yesCell Death and Disease, 2022
Receptor-interacting protein kinase 1 (RIPK1) and 3 (RIPK3) are critical regulators of programmed necrosis or necroptosis. However, the role of the RIPK1/RIPK3 signaling pathway in myocardial fibrosis and related diabetic cardiomyopathy is still unclear.
Shigang Qiao   +9 more
doaj   +1 more source

RIPK3 promotes adenovirus type 5 activity [PDF]

open access: yesCell Death & Disease, 2017
AbstractOncolytic adenoviral mutants infect human malignant cells and replicate selectively within them. This induces direct cytotoxicity that can also trigger profound innate and adaptive immune responses. However, the mechanism by which adenoviruses produce cell death remains uncertain.
Melanie Weigert   +12 more
openaire   +4 more sources

Necroptosis in bacterial infections

open access: yesFrontiers in Immunology
Necroptosis, a recently discovered form of cell-programmed death that is distinct from apoptosis, has been confirmed to play a significant role in the pathogenesis of bacterial infections in various animal models. Necroptosis is advantageous to the host,
Xing Yu   +5 more
doaj   +1 more source

RIPK3—a predictive marker for personalized immunotherapy? [PDF]

open access: yesOncoImmunology, 2016
Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells.
openaire   +3 more sources

Home - About - Disclaimer - Privacy